133 results on '"Waldstreicher, Joanne"'
Search Results
2. Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting
3. Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank
4. A Pilot Experiment in Responding to Individual Patient Requests for Compassionate Use of an Unapproved Drug: The Compassionate Use Advisory Committee (CompAC)
5. Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation
6. Drugs of unproven benefit for COVID-19: a pharma perspective on ethical allocation of available therapies
7. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
8. Sustained Decrease in Incidence of Acute Urinary Retention and Surgery With Finasteride for 6 Years in Men With Benign Prostatic Hyperplasia
9. A systemic type I 5 α-reductase inhibitor is ineffective in the treatment of acne vulgaris
10. Lowering Low Density Lipoprotein Cholesterol with Simvastatin, a Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor, Does Not Affect Luteal Function in Premenopausal Women
11. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia
12. Measuring Reversal of Hair Miniaturization in Androgenetic Alopecia by Follicular Counts in Horizontal Sections of Serial Scalp Biopsies: Results of Finasteride 1 mg Treatment of Men and Postmenopausal Women
13. Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data Sharing
14. Overview and experience of the YODA Project with clinical trial data sharing after 5 years
15. The Long-Term Effect Of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial
16. THE LONG-TERM EFFECTS OF FINASTERIDE ON BPH: RESULTS OF A FOUR-YEAR, PLACEBO-CONTROLLED STUDY
17. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia
18. Androgen antagonists: Potential role in prostate cancer prevention
19. How Johnson & Johnson Made Hard Decisions During Covid.
20. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride
21. SERUM PROSTATE SPECIFIC ANTIGEN IS A STRONG PREDICTOR OF FUTURE PROSTATE GROWTH IN MEN WITH BENIGN PROSTATIC HYPERPLASIA
22. Finasteride in the treatment of men with frontal male pattern hair loss
23. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo
24. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia
25. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy?
26. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia
27. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia
28. Managing Conflicts of Interest in Industry-Sponsored Clinical Research
29. Data Acquisition, Curation, and Use for a Continuously Learning Health System
30. Compassionate Use: A Modest Proposal
31. The need for even further progress with clinical trial data sharing efforts: patients are waiting
32. Bumps and bridges on the road to responsible sharing of clinical trial data
33. Globalized Pediatric Research
34. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia
35. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia
36. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia
37. Storage (Irritative) and Voiding (Obstructive) Symptoms as Predictors of Benign Prostatic Hyperplasia Progression and Related Outcomes
38. Lowering LDL cholesterol with simvastatin, an HMG-CoA reductase inhibitor, does not affect luteal function in women
39. Urinary Retention in Patients with BPH Treated with Finasteride or Placebo over 4 Years
40. Measuring Reversal of Hair Miniaturization in Androgenetic Alopecia by Follicular Counts in Horizontal Sections of Serial Scalp Biopsies: Results of Finasteride 1mg Treatment of Men and Postmenopausal Women
41. Patient-Perceived Importance of Negative Effects of Androgenetic Alopecia in Women
42. RELATIONSHIPS BETWEEN BASELINE SERUM PSA AND PSA CHANGES, AND PROSTATE VOLUME AND VOLUME CHANGES OVER FOUR YEARS IN PATIENTS ON PLACEBO AND FINASTERIDE
43. Filling vs. Voiding Symptoms as Predictors of Benign Prostatic Hyperplasia-Related Outcomes
44. Biologic Variability of Prostate-Specific Antigen and its Usefulness as a Marker for Prostate Cancer: Effects of Finasteride
45. Reply
46. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: Effects of finasteride
47. A multirater validation study to assess the reliability of acne lesion counting
48. The Yale Open Data Access (YODA) Project--A Mechanism for Data Sharing.
49. ANOREXIA NERVOSA PRESENTING AS MORBID EXERCISING
50. Hyperfunction of the Hypothalamic-Pituitary Axis in Women with Polycystic Ovarian Disease: Indirect Evidence for Partial Gonadotroph Desensitization*
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.